Johnson & Johnson
JNJ | NYSE
$269.47
-$0.52 (-0.19%)
At close: Sep 21, 2026, 4:00 PM ET
$268.93
-$0.54 (-0.20%)
Pre-market:
Sep 22, 2026, 6:02 AM ET
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Key Executives
| Name | Position |
|---|---|
| Joaquin Duato | Chief Executive Officer & Chairman |
| Elizabeth Forminard | Executive Vice President & Chief Legal Officer |
| James Swanson | Executive Vice President & Chief Information Officer |
| Joseph J. Wolk | Executive Vice President & Chief Financial Officer |
| Dirk Brinckman | Chief Compliance Officer |
| Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine |
| John C. Reed | Executive Vice President of Innovative Medicine and R&D |
| Kristen Blair Mulholland | Executive Vice President & Chief Human Resources Officer |
| Robert J. Decker Jr. | Controller & Chief Accounting Officer |
| Ryan Koors | Vice President of Investor Relations |
| Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 01, 2026 | 3 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 11, 2026 | N-PX | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 06, 2026 | 13F-HR | Quarterly report filed by institutional managers, ... |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 8-K | Current Report |
Johnson & Johnson
| Country | United States |
| IPO Date | Jan 1, 1962 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 141,700 |
| CEO | Joaquin Duato |
Contact Details
One Johnson & Johnson Plaza New Brunswick,
New Jersey 08933 United States
Stock Details
| Ticker Symbol | JNJ |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000200406 |
| CUSIP Number | 478160104 |
| ISIN Number | US4781601046 |
| SIC Code | 2834 |
Recent News
- 21 hours ago / benzinga.comJohnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
- 1 day ago / reuters.comJ&J's Caplyta meets main goal of bipolar mania study
- 2 days ago / 247wallst.com3 Dividend Stocks Built for Retirement to Buy in September
- 4 days ago / zacks.comJ&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
- 4 days ago / zacks.comJohnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
- 4 days ago / seekingalpha.comJohnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
- 4 days ago / marketbeat.comJohnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff
- 5 days ago / gurufocus.comJ&J Slips as Caplyta Clears a Quality-of-Life Test
- 5 days ago / 247wallst.comMonthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
- 6 days ago / defenseworld.netJohnson & Johnson $JNJ Shares Sold by HighTower Advisors LLC
Add to Watchlist
Select watchlists to add or remove JNJ